CD274 and non-small cell lung carcinoma: Notably, ICIs such as nivolumab, a monoclonal antibody targeting the PD-1 receptor, has demonstrated significant efficacy in NSCLC by disrupting the interaction of the PD-1 receptor with its ligands PD-L1 and PD-L2, thereby inhibiting the cellular immune response [19,20].